Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 -3.13%69 5-Year Yield-on-Cost % is 1.51 as of Jul. 31, 2026, which is 50% below its 10-year median of 3.04. GuruFocus rates TPE:4119 with a GF Score™ of 69/100 and a GF Value™ of NT$94.27 (Possible Value Trap). The stock has 10 warning signs investors should review. Among 512 Drug Manufacturers companies, Sci Pharmtech ranks worse than 62.7% on this metric.
Sci Pharmtech's yield on cost for the quarter that ended in Mar. 2026 was 1.51.
The historical rank and industry rank for Sci Pharmtech's 5-Year Yield-on-Cost % or its related term are showing as below:
TPE:4119'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.25 Med: 3.04 Max: 7.49
Current: 1.51
During the past 13 years, Sci Pharmtech's highest Yield on Cost was 7.49. The lowest was 0.25. And the median was 3.04.
TPE:4119's 5-Year Yield-on-Cost % is ranked worse than 62.7% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs TPE:4119: 1.51
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sci Pharmtech 5-Year Yield-on-Cost % Related Terms
TPE:4119 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Sci Pharmtech is calculated as
Sci Pharmtech (TPE:4119) has a 5-Year Yield-on-Cost % of 1.51 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sci Pharmtech and its competitors. This is 50% below median its historical median of 3.04. Over the past decade, Sci Pharmtech's 5-Year Yield-on-Cost % has ranged from 0.25 to 7.49. According to the industry distribution chart, Sci Pharmtech ranks #321 out of 512 companies in the Drug Manufacturers industry, placing it in the top 62.7%.
Is Sci Pharmtech's 5-Year Yield-on-Cost % too high?
Sci Pharmtech's current 5-Year Yield-on-Cost % of 1.51 is 50% below median its 10-year median of 3.04. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 7.49. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Sci Pharmtech's value of 1.51 is 34.9% below this industry median. Based on the distribution chart, Sci Pharmtech ranks #321 out of 512 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #321 out of 512 companies for 5-Year Yield-on-Cost %. This places Sci Pharmtech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Sci Pharmtech's value of 1.51 is 34.9% below this benchmark. Historically, Sci Pharmtech's own 5-Year Yield-on-Cost % has ranged from 0.25 to 7.49 over the past decade. While the company's 10-year median is 3.04 vs. the industry median of 2.32, Sci Pharmtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current 5-Year Yield-on-Cost % of 1.51 is 34.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current 5-Year Yield-on-Cost % is 1.51, which is 50% below median its own 10-year median of 3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$94.27, compared to a current price of NT$48.00 — trading 49.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.51, which is 50% below median its 10-year median of 3.04 and 34.9% below the Drug Manufacturers industry median of 2.32. Sci Pharmtech's overall GF Score™ is 69/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current 5-Year Yield-on-Cost % is 1.51 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$48.00 is trading 49.1% below its estimated GF Value™ of NT$94.27.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
5-Year Yield-on-Cost %: 1.51 (50% below median its 10-year median of 3.04)
GF Value™: NT$94.27 vs. price of NT$48.00 (49.1% below fair value)
Industry Position: 34.9% below the Drug Manufacturers median (#321 of 512)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
69GF Score
Get the complete analysis for TPE:4119
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
